APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine Imaging Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Medicine Imaging Agents Market Outlook and Growth Opportunities 2026

Report ID 173917110426 December 2025195 pages

Choose your research edition.

Industry ResearchNuclear Medicine Imaging Agents Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Imaging Agents Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Imaging Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Imaging Agents Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Imaging Agents Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Nuclear Medicine Imaging Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Medicine Imaging Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nuclear Medicine Imaging Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nuclear Medicine Imaging Agents market include Jubilant Pharma Limited, Foshan Rui Diao Pharmaceutical, Yantai Dongcheng, Navidea, Mallinckrodt, Lantheus, Guerbet, GE HealthCare and Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nuclear Medicine Imaging Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Medicine Imaging Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Medicine Imaging Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nuclear Medicine Imaging Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Nuclear Medicine Imaging Agents Segment by Company

Jubilant Pharma Limited

Foshan Rui Diao Pharmaceutical

Yantai Dongcheng

Navidea

Mallinckrodt

Lantheus

Guerbet

GE HealthCare

Eli Lilly and Company

Cardinal Health

Bracco Diagnostic

Blue Earth Diagnostics

Bayer AG

Abx Advanced Biochemical

Nuclear Medicine Imaging Agents Segment by Type

Nitrogen 13 Labeling

Technetium 99 Labeling

Fluorine 18 Labeling

Carbon 11 Labeling

Oxygen 15 Labeling

Others

Nuclear Medicine Imaging Agents Segment by Application

Clinical Stage

Early Diagnosis

Treatment Evaluation

Nuclear Medicine Imaging Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nuclear Medicine Imaging Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nuclear Medicine Imaging Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Medicine Imaging Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Medicine Imaging Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Imaging Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Imaging Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Imaging Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nuclear Medicine Imaging Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine Imaging Agents industry.

Chapter 3: Detailed analysis of Nuclear Medicine Imaging Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nuclear Medicine Imaging Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nuclear Medicine Imaging Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Medicine Imaging Agents Industry Trends Table 2. Nuclear Medicine Imaging Agents Industry Drivers Table 3. Nuclear Medicine Imaging Agents Industry Opportunities and Challenges Table 4. Nuclear Medicine Imaging Agents Industry Restraints Table 5. Global Nuclear Medicine Imaging Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Medicine Imaging Agents Revenue Share by Company (2021-2026) Table 7. Global Nuclear Medicine Imaging Agents Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nuclear Medicine Imaging Agents Sales Volume Share by Company (2021-2026) Table 9. Global Nuclear Medicine Imaging Agents Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nuclear Medicine Imaging Agents Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nuclear Medicine Imaging Agents Key Company Manufacturing Base & Headquarters Table 12. Global Nuclear Medicine Imaging Agents Company, Product Type & Application Table 13. Global Nuclear Medicine Imaging Agents Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nuclear Medicine Imaging Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Nitrogen 13 Labeling Table 18. Significant Companies of Technetium 99 Labeling Table 19. Significant Companies of Fluorine 18 Labeling Table 20. Significant Companies of Carbon 11 Labeling Table 21. Significant Companies of Oxygen 15 Labeling Table 22. Significant Companies of Others Table 23. Global Nuclear Medicine Imaging Agents Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Nuclear Medicine Imaging Agents Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Nuclear Medicine Imaging Agents Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Nuclear Medicine Imaging Agents Sales Volume Share by Type (2021-2026) Table 27. Global Nuclear Medicine Imaging Agents Sales Volume Share by Type (2027-2032) Table 28. Global Nuclear Medicine Imaging Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nuclear Medicine Imaging Agents Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Nuclear Medicine Imaging Agents Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Nuclear Medicine Imaging Agents Sales Value Share by Type (2021-2026) Table 32. Global Nuclear Medicine Imaging Agents Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinical Stage Table 34. Significant Companies of Early Diagnosis Table 35. Significant Companies of Treatment Evaluation Table 36. Global Nuclear Medicine Imaging Agents Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Nuclear Medicine Imaging Agents Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Nuclear Medicine Imaging Agents Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Nuclear Medicine Imaging Agents Sales Volume Share by Application (2021-2026) Table 40. Global Nuclear Medicine Imaging Agents Sales Volume Share by Application (2027-2032) Table 41. Global Nuclear Medicine Imaging Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Nuclear Medicine Imaging Agents Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Nuclear Medicine Imaging Agents Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Nuclear Medicine Imaging Agents Sales Value Share by Application (2021-2026) Table 45. Global Nuclear Medicine Imaging Agents Sales Value Share by Application (2027-2032) Table 46. Global Nuclear Medicine Imaging Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Nuclear Medicine Imaging Agents Sales by Region (2021-2026) & (K Units) Table 48. Global Nuclear Medicine Imaging Agents Sales Market Share by Region (2021-2026) Table 49. Global Nuclear Medicine Imaging Agents Sales by Region (2027-2032) & (K Units) Table 50. Global Nuclear Medicine Imaging Agents Sales Market Share by Region (2027-2032) Table 51. Global Nuclear Medicine Imaging Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Nuclear Medicine Imaging Agents Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Nuclear Medicine Imaging Agents Sales Value Share by Region (2021-2026) Table 54. Global Nuclear Medicine Imaging Agents Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Nuclear Medicine Imaging Agents Sales Value Share by Region (2027-2032) Table 56. Global Nuclear Medicine Imaging Agents Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Nuclear Medicine Imaging Agents Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Nuclear Medicine Imaging Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Nuclear Medicine Imaging Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Nuclear Medicine Imaging Agents Sales by Country (2021-2026) & (K Units) Table 61. Global Nuclear Medicine Imaging Agents Sales Market Share by Country (2021-2026) Table 62. Global Nuclear Medicine Imaging Agents Sales by Country (2027-2032) & (K Units) Table 63. Global Nuclear Medicine Imaging Agents Sales Market Share by Country (2027-2032) Table 64. Global Nuclear Medicine Imaging Agents Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Nuclear Medicine Imaging Agents Sales Value Market Share by Country (2021-2026) Table 66. Global Nuclear Medicine Imaging Agents Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Nuclear Medicine Imaging Agents Sales Value Market Share by Country (2027-2032) Table 68. Jubilant Pharma Limited Company Information Table 69. Jubilant Pharma Limited Business Overview Table 70. Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio Table 72. Jubilant Pharma Limited Recent Development Table 73. Foshan Rui Diao Pharmaceutical Company Information Table 74. Foshan Rui Diao Pharmaceutical Business Overview Table 75. Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio Table 77. Foshan Rui Diao Pharmaceutical Recent Development Table 78. Yantai Dongcheng Company Information Table 79. Yantai Dongcheng Business Overview Table 80. Yantai Dongcheng Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio Table 82. Yantai Dongcheng Recent Development Table 83. Navidea Company Information Table 84. Navidea Business Overview Table 85. Navidea Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Navidea Nuclear Medicine Imaging Agents Product Portfolio Table 87. Navidea Recent Development Table 88. Mallinckrodt Company Information Table 89. Mallinckrodt Business Overview Table 90. Mallinckrodt Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio Table 92. Mallinckrodt Recent Development Table 93. Lantheus Company Information Table 94. Lantheus Business Overview Table 95. Lantheus Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lantheus Nuclear Medicine Imaging Agents Product Portfolio Table 97. Lantheus Recent Development Table 98. Guerbet Company Information Table 99. Guerbet Business Overview Table 100. Guerbet Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Guerbet Nuclear Medicine Imaging Agents Product Portfolio Table 102. Guerbet Recent Development Table 103. GE HealthCare Company Information Table 104. GE HealthCare Business Overview Table 105. GE HealthCare Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio Table 107. GE HealthCare Recent Development Table 108. Eli Lilly and Company Company Information Table 109. Eli Lilly and Company Business Overview Table 110. Eli Lilly and Company Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio Table 112. Eli Lilly and Company Recent Development Table 113. Cardinal Health Company Information Table 114. Cardinal Health Business Overview Table 115. Cardinal Health Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio Table 117. Cardinal Health Recent Development Table 118. Bracco Diagnostic Company Information Table 119. Bracco Diagnostic Business Overview Table 120. Bracco Diagnostic Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio Table 122. Bracco Diagnostic Recent Development Table 123. Blue Earth Diagnostics Company Information Table 124. Blue Earth Diagnostics Business Overview Table 125. Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio Table 127. Blue Earth Diagnostics Recent Development Table 128. Bayer AG Company Information Table 129. Bayer AG Business Overview Table 130. Bayer AG Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bayer AG Nuclear Medicine Imaging Agents Product Portfolio Table 132. Bayer AG Recent Development Table 133. Abx Advanced Biochemical Company Information Table 134. Abx Advanced Biochemical Business Overview Table 135. Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio Table 137. Abx Advanced Biochemical Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Nuclear Medicine Imaging Agents Distributors List Table 141. Nuclear Medicine Imaging Agents Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Nuclear Medicine Imaging Agents Product Image Figure 2. Global Nuclear Medicine Imaging Agents Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nuclear Medicine Imaging Agents Sales (2021-2032) & (K Units) Figure 5. Global Nuclear Medicine Imaging Agents Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nuclear Medicine Imaging Agents Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Nitrogen 13 Labeling Image Figure 10. Technetium 99 Labeling Image Figure 11. Fluorine 18 Labeling Image Figure 12. Carbon 11 Labeling Image Figure 13. Oxygen 15 Labeling Image Figure 14. Others Image Figure 15. Global Nuclear Medicine Imaging Agents Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Nuclear Medicine Imaging Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Nuclear Medicine Imaging Agents Sales Volume Share by Type (2021-2032) Figure 18. Global Nuclear Medicine Imaging Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nuclear Medicine Imaging Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nuclear Medicine Imaging Agents Sales Value Share by Type (2021-2032) Figure 21. Clinical Stage Image Figure 22. Early Diagnosis Image Figure 23. Treatment Evaluation Image Figure 24. Global Nuclear Medicine Imaging Agents Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Nuclear Medicine Imaging Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Nuclear Medicine Imaging Agents Sales Volume Share by Application (2021-2032) Figure 27. Global Nuclear Medicine Imaging Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Nuclear Medicine Imaging Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Nuclear Medicine Imaging Agents Sales Value Share by Application (2021-2032) Figure 30. Global Nuclear Medicine Imaging Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Nuclear Medicine Imaging Agents Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Nuclear Medicine Imaging Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Nuclear Medicine Imaging Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 35. North America Nuclear Medicine Imaging Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Nuclear Medicine Imaging Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Nuclear Medicine Imaging Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 41. South America Nuclear Medicine Imaging Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Nuclear Medicine Imaging Agents Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Nuclear Medicine Imaging Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Nuclear Medicine Imaging Agents Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Nuclear Medicine Imaging Agents Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Nitrogen 13 Labeling
  • Technetium 99 Labeling
  • Fluorine 18 Labeling
  • Carbon 11 Labeling
  • Oxygen 15 Labeling
  • Others
Applications
  • Clinical Stage
  • Early Diagnosis
  • Treatment Evaluation
Companies covered
  • Jubilant Pharma Limited
  • Foshan Rui Diao Pharmaceutical
  • Yantai Dongcheng
  • Navidea
  • Mallinckrodt
  • Lantheus
  • Guerbet
  • GE HealthCare
  • Eli Lilly and Company
  • Cardinal Health
  • Bracco Diagnostic
  • Blue Earth Diagnostics
  • Bayer AG
  • Abx Advanced Biochemical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  4. 1.2.2 Global Nuclear Medicine Imaging Agents Sales Volume (2021-2032)
  5. 1.2.3 Global Nuclear Medicine Imaging Agents Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nuclear Medicine Imaging Agents Market Dynamics
  1. 2.1 Nuclear Medicine Imaging Agents Industry Trends
  2. 2.2 Nuclear Medicine Imaging Agents Industry Drivers
  3. 2.3 Nuclear Medicine Imaging Agents Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Imaging Agents Industry Restraints
3 Nuclear Medicine Imaging Agents Market by Company
  1. 3.1 Global Nuclear Medicine Imaging Agents Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Medicine Imaging Agents Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Medicine Imaging Agents Sales Volume by Company (2021-2026)
  4. 3.4 Global Nuclear Medicine Imaging Agents Average Price by Company (2021-2026)
  5. 3.5 Global Nuclear Medicine Imaging Agents Company Ranking (2024-2026)
  6. 3.6 Global Nuclear Medicine Imaging Agents Company Manufacturing Base and Headquarters
  7. 3.7 Global Nuclear Medicine Imaging Agents Company Product Type and Application
  8. 3.8 Global Nuclear Medicine Imaging Agents Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nuclear Medicine Imaging Agents Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nuclear Medicine Imaging Agents Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nuclear Medicine Imaging Agents Market by Type
  1. 4.1 Nuclear Medicine Imaging Agents Type Introduction
  2. 4.1.1 Nitrogen 13 Labeling
  3. 4.1.2 Technetium 99 Labeling
  4. 4.1.3 Fluorine 18 Labeling
  5. 4.1.4 Carbon 11 Labeling
  6. 4.1.5 Oxygen 15 Labeling
  7. 4.1.6 Others
  8. 4.2 Global Nuclear Medicine Imaging Agents Sales Volume by Type
  9. 4.2.1 Global Nuclear Medicine Imaging Agents Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Nuclear Medicine Imaging Agents Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Nuclear Medicine Imaging Agents Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Nuclear Medicine Imaging Agents Sales Value by Type
  13. 4.3.1 Global Nuclear Medicine Imaging Agents Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Nuclear Medicine Imaging Agents Sales Value by Type (2021-2032)
  15. 4.3.3 Global Nuclear Medicine Imaging Agents Sales Value Share by Type (2021-2032)
5 Nuclear Medicine Imaging Agents Market by Application
  1. 5.1 Nuclear Medicine Imaging Agents Application Introduction
  2. 5.1.1 Clinical Stage
  3. 5.1.2 Early Diagnosis
  4. 5.1.3 Treatment Evaluation
  5. 5.2 Global Nuclear Medicine Imaging Agents Sales Volume by Application
  6. 5.2.1 Global Nuclear Medicine Imaging Agents Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nuclear Medicine Imaging Agents Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Nuclear Medicine Imaging Agents Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Nuclear Medicine Imaging Agents Sales Value by Application
  10. 5.3.1 Global Nuclear Medicine Imaging Agents Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nuclear Medicine Imaging Agents Sales Value by Application (2021-2032)
  12. 5.3.3 Global Nuclear Medicine Imaging Agents Sales Value Share by Application (2021-2032)
6 Nuclear Medicine Imaging Agents Regional Sales and Value Analysis
  1. 6.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Medicine Imaging Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Nuclear Medicine Imaging Agents Sales by Region: 2021-2026
  4. 6.2.2 Global Nuclear Medicine Imaging Agents Sales by Region (2027-2032)
  5. 6.3 Global Nuclear Medicine Imaging Agents Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nuclear Medicine Imaging Agents Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nuclear Medicine Imaging Agents Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nuclear Medicine Imaging Agents Sales Value by Region (2027-2032)
  9. 6.5 Global Nuclear Medicine Imaging Agents Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  12. 6.6.2 North America Nuclear Medicine Imaging Agents Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  15. 6.7.2 Europe Nuclear Medicine Imaging Agents Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nuclear Medicine Imaging Agents Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  21. 6.9.2 South America Nuclear Medicine Imaging Agents Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nuclear Medicine Imaging Agents Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nuclear Medicine Imaging Agents Sales Value Share by Country, 2025 VS 2032
7 Nuclear Medicine Imaging Agents Country-level Sales and Value Analysis
  1. 7.1 Global Nuclear Medicine Imaging Agents Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Medicine Imaging Agents Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nuclear Medicine Imaging Agents Sales by Country (2021-2032)
  4. 7.3.1 Global Nuclear Medicine Imaging Agents Sales by Country (2021-2026)
  5. 7.3.2 Global Nuclear Medicine Imaging Agents Sales by Country (2027-2032)
  6. 7.4 Global Nuclear Medicine Imaging Agents Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nuclear Medicine Imaging Agents Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nuclear Medicine Imaging Agents Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nuclear Medicine Imaging Agents Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nuclear Medicine Imaging Agents Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nuclear Medicine Imaging Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Jubilant Pharma Limited
  2. 8.1.1 Jubilant Pharma Limited Company Information
  3. 8.1.2 Jubilant Pharma Limited Business Overview
  4. 8.1.3 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Jubilant Pharma Limited Nuclear Medicine Imaging Agents Product Portfolio
  6. 8.1.5 Jubilant Pharma Limited Recent Developments
  7. 8.2 Foshan Rui Diao Pharmaceutical
  8. 8.2.1 Foshan Rui Diao Pharmaceutical Company Information
  9. 8.2.2 Foshan Rui Diao Pharmaceutical Business Overview
  10. 8.2.3 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Foshan Rui Diao Pharmaceutical Nuclear Medicine Imaging Agents Product Portfolio
  12. 8.2.5 Foshan Rui Diao Pharmaceutical Recent Developments
  13. 8.3 Yantai Dongcheng
  14. 8.3.1 Yantai Dongcheng Company Information
  15. 8.3.2 Yantai Dongcheng Business Overview
  16. 8.3.3 Yantai Dongcheng Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Yantai Dongcheng Nuclear Medicine Imaging Agents Product Portfolio
  18. 8.3.5 Yantai Dongcheng Recent Developments
  19. 8.4 Navidea
  20. 8.4.1 Navidea Company Information
  21. 8.4.2 Navidea Business Overview
  22. 8.4.3 Navidea Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Navidea Nuclear Medicine Imaging Agents Product Portfolio
  24. 8.4.5 Navidea Recent Developments
  25. 8.5 Mallinckrodt
  26. 8.5.1 Mallinckrodt Company Information
  27. 8.5.2 Mallinckrodt Business Overview
  28. 8.5.3 Mallinckrodt Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mallinckrodt Nuclear Medicine Imaging Agents Product Portfolio
  30. 8.5.5 Mallinckrodt Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Nuclear Medicine Imaging Agents Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 Guerbet
  38. 8.7.1 Guerbet Company Information
  39. 8.7.2 Guerbet Business Overview
  40. 8.7.3 Guerbet Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Guerbet Nuclear Medicine Imaging Agents Product Portfolio
  42. 8.7.5 Guerbet Recent Developments
  43. 8.8 GE HealthCare
  44. 8.8.1 GE HealthCare Company Information
  45. 8.8.2 GE HealthCare Business Overview
  46. 8.8.3 GE HealthCare Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GE HealthCare Nuclear Medicine Imaging Agents Product Portfolio
  48. 8.8.5 GE HealthCare Recent Developments
  49. 8.9 Eli Lilly and Company
  50. 8.9.1 Eli Lilly and Company Company Information
  51. 8.9.2 Eli Lilly and Company Business Overview
  52. 8.9.3 Eli Lilly and Company Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly and Company Nuclear Medicine Imaging Agents Product Portfolio
  54. 8.9.5 Eli Lilly and Company Recent Developments
  55. 8.10 Cardinal Health
  56. 8.10.1 Cardinal Health Company Information
  57. 8.10.2 Cardinal Health Business Overview
  58. 8.10.3 Cardinal Health Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Cardinal Health Nuclear Medicine Imaging Agents Product Portfolio
  60. 8.10.5 Cardinal Health Recent Developments
  61. 8.11 Bracco Diagnostic
  62. 8.11.1 Bracco Diagnostic Company Information
  63. 8.11.2 Bracco Diagnostic Business Overview
  64. 8.11.3 Bracco Diagnostic Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bracco Diagnostic Nuclear Medicine Imaging Agents Product Portfolio
  66. 8.11.5 Bracco Diagnostic Recent Developments
  67. 8.12 Blue Earth Diagnostics
  68. 8.12.1 Blue Earth Diagnostics Company Information
  69. 8.12.2 Blue Earth Diagnostics Business Overview
  70. 8.12.3 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Blue Earth Diagnostics Nuclear Medicine Imaging Agents Product Portfolio
  72. 8.12.5 Blue Earth Diagnostics Recent Developments
  73. 8.13 Bayer AG
  74. 8.13.1 Bayer AG Company Information
  75. 8.13.2 Bayer AG Business Overview
  76. 8.13.3 Bayer AG Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bayer AG Nuclear Medicine Imaging Agents Product Portfolio
  78. 8.13.5 Bayer AG Recent Developments
  79. 8.14 Abx Advanced Biochemical
  80. 8.14.1 Abx Advanced Biochemical Company Information
  81. 8.14.2 Abx Advanced Biochemical Business Overview
  82. 8.14.3 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Abx Advanced Biochemical Nuclear Medicine Imaging Agents Product Portfolio
  84. 8.14.5 Abx Advanced Biochemical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nuclear Medicine Imaging Agents Value Chain Analysis
  2. 9.1.1 Nuclear Medicine Imaging Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nuclear Medicine Imaging Agents Sales Mode & Process
  6. 9.2 Nuclear Medicine Imaging Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nuclear Medicine Imaging Agents Distributors
  9. 9.2.3 Nuclear Medicine Imaging Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst